Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

PHASE4CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions

Cerebral InfarctionTIA

Interventions

DRUG

Rivaroxaban

Rivaroxaban 15-20 mg daily

Trial Locations (1)

General Hospital of ShenYang Military Region, Shenyang

All Listed Sponsors

lead

General Hospital of Shenyang Military Region

OTHER

NCT03749057 - Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation | Biotech Hunter | Biotech Hunter